{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:43:56Z","timestamp":1789011836631,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0583-7","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:16:43Z","timestamp":1524151003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Maisnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Obreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blaedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"583_CR1","unstructured":"National Cancer Institute: SEER Cancer Statistics Factsheets: Myeloma. Surveillance, Epidemiology, and End Results Program website. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html . Accessed 6 Oct 2016."},{"key":"583_CR2","unstructured":"World Health Organization: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer website. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx . Accessed 5 Dec 2016."},{"issue":"Suppl","key":"583_CR3","doi-asserted-by":"crossref","first-page":"Abstract 8095","DOI":"10.1200\/jco.2012.30.15_suppl.8095","volume":"30","author":"B Durie","year":"2012","unstructured":"Durie B, Moreau P, Sonneveld P, Morgan GJ, Lahuerta JJ, Beksac M, et al. Regional differences in the treatment approaches for relapsed multiple myeloma: an IMF study. J Clin Oncol. 2012;30(Suppl):Abstract 8095.","journal-title":"J Clin Oncol"},{"key":"583_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22:417\u201326.","journal-title":"Support Care Cancer"},{"key":"583_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867\u201374.","journal-title":"Mayo Clin Proc"},{"key":"583_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, et al. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Hematol. 2012;89:311\u20139.","journal-title":"Eur J Hematol"},{"key":"583_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1053\/j.seminoncol.2013.07.007","volume":"40","author":"RZ Orlowski","year":"2013","unstructured":"Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013;40:634\u201351.","journal-title":"Semin Oncol"},{"key":"583_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2710.2009.01153.x","volume":"36","author":"X Armoiry","year":"2011","unstructured":"Armoiry X, Fagnani F, Benboubker L, Facon T, Fermand JP, Hulin C, et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J Clin Pharm Ther. 2011;36:19\u201326.","journal-title":"J Clin Pharm Ther"},{"key":"583_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","volume":"18","author":"LP Garrison Jr","year":"2013","unstructured":"Garrison LP Jr, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 2013;18:27\u201336.","journal-title":"Oncologist"},{"key":"583_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.clinthera.2008.09.003","volume":"30","author":"O Ghatnekar","year":"2008","unstructured":"Ghatnekar O, Alveg\u00e5rd T, Conradi N, Lenhoff S, Mellqvist UH, Persson U, et al. Direct hospital resource utilization and costs of treating patients with multiple myeloma in southwest Sweden: a 5-year retrospective analysis. Clin Ther. 2008;30:1704\u201313.","journal-title":"Clin Ther"},{"key":"583_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327\u201337.","journal-title":"Lancet Oncol."},{"key":"583_CR12","unstructured":"National Comprehensive Cancer Network website. https:\/\/www.nccn.org\/ . Accessed 15 Jan 2017."},{"key":"583_CR13","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/leu.2015.209","volume":"29","author":"SZ Usmani","year":"2015","unstructured":"Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia. 2015;29:2119\u201325.","journal-title":"Leukemia"},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New Engl J Med. 2012;366:1782\u201391.","journal-title":"New Engl J Med."},{"key":"583_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. New Engl J Med. 2014;371:906\u201317.","journal-title":"New Engl J Med."},{"issue":"Suppl 3","key":"583_CR16","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clml.2015.07.193","volume":"15","author":"C Cerrato","year":"2015","unstructured":"Cerrato C, Gay F, Petrucci MT, Pellegrino M, Gaidano G, Offidani M, et al. Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl 3):e54.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"583_CR17","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. New Engl J Med. 2012;366:1770\u201381.","journal-title":"New Engl J Med"},{"key":"583_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32:634\u201340.","journal-title":"J Clin Oncol"},{"key":"583_CR19","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"30","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;30:3459\u201366.","journal-title":"J Clin Oncol"},{"key":"583_CR20","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946\u201355.","journal-title":"J Clin Oncol"},{"key":"583_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/17474086.2016.1196127","volume":"9","author":"P Musto","year":"2016","unstructured":"Musto P, Montefusco V. Are maintenance and continuous therapies indicated for every patient with multiple myeloma? Expert Rev Hematol. 2016;9:743\u201351.","journal-title":"Expert Rev Hematol"},{"key":"583_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicentre study. Lancet Oncol. 2015;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"583_CR23","first-page":"179","volume":"12","author":"PG Richardson","year":"2014","unstructured":"Richardson PG. Update on proteasome inhibitors in multiple myeloma. Clin Adv Hematol Oncol. 2014;12:179\u201381.","journal-title":"Clin Adv Hematol Oncol"},{"key":"583_CR24","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817\u201325.","journal-title":"Blood"},{"key":"583_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New Engl J Med. 2015;372:142\u201352.","journal-title":"New Engl J Med."},{"key":"583_CR26","first-page":"23","volume":"8","author":"D Sugumar","year":"2015","unstructured":"Sugumar D, Keller J, Vij R. Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmacogenomics Pers Med. 2015;8:23\u201333.","journal-title":"Pharmacogenomics Pers Med"},{"key":"583_CR27","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2013-07-513366","volume":"122","author":"M Wang","year":"2013","unstructured":"Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013;122:2284\u201390.","journal-title":"Blood"},{"key":"583_CR28","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","volume":"19","author":"R Niesvizky","year":"2013","unstructured":"Niesvizky R, Martin TG 3rd, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, et al. Phase 1b dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013;19:2248\u201356.","journal-title":"Clin Cancer Res"},{"key":"583_CR29","doi-asserted-by":"publisher","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018; https:\/\/doi.org\/10.1200\/JCO.2017.76.5032 .","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"583_CR30","volume-title":"Modelling survival data in medical research. 2nd ed","author":"D Collet","year":"2003","unstructured":"Collet D. Modelling survival data in medical research. 2nd ed. New York: Chapman & Hall; 2003."},{"key":"583_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35\u201344.","journal-title":"Stat Med"},{"key":"583_CR32","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"583_CR33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med. 2016;375:1319\u201331.","journal-title":"New Engl J Med."},{"key":"583_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. New Engl J Med. 2015;373:621\u201331.","journal-title":"New Engl J Med."},{"key":"583_CR35","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med. 2016;374:1621\u201334.","journal-title":"New Engl J Med."},{"issue":"4","key":"583_CR36","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1038\/bcj.2017.31","volume":"7","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Stewart AK, Rajkumar V, Masszi T, Oriol A, Hajek R, et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7(4):e554.","journal-title":"Blood Cancer J"},{"key":"583_CR37","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","volume":"28","author":"A Chanan-Khan","year":"2010","unstructured":"Chanan-Khan A, Giral S. Complete response in multiple myeloma and the impact of novel agent. J Clin Oncol. 2010;28:2612.","journal-title":"J Clin Oncol"},{"key":"583_CR38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"H Van de Velde","year":"2007","unstructured":"Van de Velde H, Liu X, Chen G, Xiangyang L, Gang C, Cakan A, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399\u2013\u2212406.","journal-title":"Haematologica"},{"key":"583_CR39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/leu.2013.220","volume":"28","author":"S Lonial","year":"2014","unstructured":"Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28:258\u201368.","journal-title":"Leukemia"},{"key":"583_CR40","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome. Blood. 2007;109:3489\u201395.","journal-title":"Blood"},{"key":"583_CR41","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/leu.2009.273","volume":"24","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexam\u00e9thasone. Leukemia. 2010;24:623\u20138.","journal-title":"Leukemia"},{"key":"583_CR42","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2014.117077","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100:1327\u201333.","journal-title":"Haematologica"},{"key":"583_CR43","first-page":"5","volume":"4","author":"SE Kurtin","year":"2013","unstructured":"Kurtin SE. Relapsed or relapsed\/refractory multiple myeloma. J Adv Pract Oncol. 2013;4:5\u201314.","journal-title":"J Adv Pract Oncol"},{"key":"583_CR44","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","volume":"9","author":"S Jagannath","year":"2016","unstructured":"Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, et al. Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol. 2016;9:707\u201317.","journal-title":"Expert Rev Hematol"},{"key":"583_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95\u2013103.","journal-title":"Curr Med Res Opin"},{"key":"583_CR46","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, \u0160pi\u010dka I, Masszi T, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128:1174\u201380.","journal-title":"Blood"},{"key":"583_CR47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ajh.23933","volume":"90","author":"MV Mateos","year":"2015","unstructured":"Mateos MV, Richardson PG, Dimopoulos MA, Palumbo A, Anderson KC, Shi H, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015;90:314\u20139.","journal-title":"Am J Hematol"},{"key":"583_CR48","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a front-line treatment for multiple myeloma. Blood. 2012;120:1801\u20139.","journal-title":"Blood"},{"issue":"Suppl","key":"583_CR49","doi-asserted-by":"crossref","first-page":"Abstract 8543","DOI":"10.1200\/jco.2013.31.15_suppl.8543","volume":"31","author":"AJ Jakubowiak","year":"2013","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Jasielec J, McDonnell K, Lebovic D, et al. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. J Clin Oncol. 2013;31(Suppl):Abstract 8543.","journal-title":"J Clin Oncol"},{"key":"583_CR50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood.V122.21.538.538","volume":"122","author":"N Korde","year":"2013","unstructured":"Korde N, Zingone A, Kwok ML, Manasanch EE, Bhutani M, Tageja N, et al. Phase II clinical and correlative study carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. Blood. 2013;122:538.","journal-title":"Blood"},{"key":"583_CR51","unstructured":"European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003790\/WC500197695.pdf . Accessed 24 Feb 2017."}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0583-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:41:36Z","timestamp":1604191296000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0583-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0583-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"12 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"All patients provided informed consent. The study was performed according to the Declaration of Helsinki. The study protocol, amendments, protocol clarification letters, informed consent forms, subject dosing diaries, advertisements, and health-related quality of life questionnaires were approved by the institutional review boards of all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MD\u2014consultancy for Amgen, Celgene, Janssen, Novartis, and Takeda. MW\u2014research funding from Pharmacyclics, Juno Therapeutics, Acerta Pharma, Celgene, BeiGene, Kite Pharma, Onyx, Asana BioSciences, and Janssen; consultancy for Acerta Pharma and Janssen. VM\u2014grants from the Binding Site; personal fees from Amgen, BMS, Celgene, and Janssen-Cilag. JM\u2014no conflicts of interest to disclose. WB\u2014grants and research funding from Celgene and Amgen Inc. M-VM\u2014personal fees from Amgen, Celgene, Janssen, and Takeda. MO and JB\u2014employment and stock ownership in Amgen, Inc. PM\u2014consultancy for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"49"}}